CA - Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats
2025-10-27 17:08:35 ET
Investment Overview: Novartis Set To Acquire Avidity - Rationale & Commentary
Yesterday, the Swiss Pharma giant Novartis AG ( NVS ) - the world's fourth most valuable Pharma by market cap, currently ~$249bn - announced that it would acquire the RNA specialist drug developer Avidity Biosciences, Inc. ( RNA ) for $72 per share, a premium of 46% to Avidity stock's Friday closing price, in a deal valued overall at ~$12bn on a fully diluted basis....
Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats